Vir Biotechnology 周三表示，已与吉利德科学签署价值高达 18.8 亿美元的合作协议，旨在发现并开发针对实体瘤的新型癌症治疗方法。该公司股票在盘前交易中因该公告上涨超过 10%。
Vir Biotechnology said on Wednesday it had signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop new cancer treatments for solid tumors.
根据协议，Vir 将获得 9000 万美元的预付款，并有资格获得最高 4500 万美元的近期临床前里程碑付款以及最高 17.4 亿美元的未来开发、监管和商业化付款。公司还将有资格获得净销售额的分层特许权使用费，比例从个位数高端到双位数低端。
Shares of Vir rose more than 10% in premarket trading following the announcement.
该合作旨在设计三种新型双掩蔽 T 细胞激活剂候选药物，以引导免疫系统摧毁实体瘤中的癌细胞。Vir 将使用其 PRO-XTEN 掩蔽技术和专有的 dAIsY AI 平台来设计这些药物候选物。公司将负责实验药物的早期研究和设计，而吉利德将拥有通过临床测试、制造和商业化推进这些药物的独家权利。
Under the agreement, Vir will receive $90 million upfront and be eligible to receive up to $45 million in near-term preclinical milestones and up to $1.74 billion in future development, regulatory and commercial payments, the company said It will also be eligible for tiered royalties on net sales ranging from high single digits to low double digits The partnership aims to engineer three novel dual-masked T-cell engager candidates to direct the immune system to destroy cancer cells in solid tumors Vir will use its PRO-XTEN masking technology and proprietary dAIsY AI platform to design the drug candidates The company will be responsible for the early research and design of the experimental drugs, while Gilead will hold the exclusive rights to advance them through clinical testing, manufacturing and commercialization